论文部分内容阅读
目的:观察中药复方苦参注射液联合肝动脉栓塞化疗术(TACE)治疗原发性肝癌的临床疗效。方法:将78例原发性肝癌患者随机分为对照组(单纯应用TACE)和实验组(TACE联合复方苦参注射液)各39例,评价比较两组患者的近期疗效及治疗前后相关指标水平。结果:经过治疗,实验组患者临床总有效率(76.9%)显著高于对照组(61.5%),实验组患者AFP值及肿瘤体积明显小于对照组,KPS评分升高幅度和Child-pugh评分降低幅度显著高于对照组,差异均具有统计学意义(P<0.05)。结论:采用TACE联合复方苦参注射液治疗原发性肝癌临床疗效显著,可有效改善患者生存质量,降低不良反应发生率,减轻患者痛苦,值得临床推广应用。
Objective: To observe the curative effect of compound kushen injection and transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Methods: Seventy-eight patients with primary liver cancer were randomly divided into control group (TACE alone) and experimental group (TACE combined with Kushen injection) in 39 cases. The curative effect and the related indexes before and after treatment were compared between the two groups . Results: After treatment, the total clinical effective rate (76.9%) in the experimental group was significantly higher than that in the control group (61.5%). The AFP value and tumor volume in the experimental group were significantly lower than those in the control group. The KPS score and Child-pugh score were decreased The amplitude was significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion: TACE combined with Compound Kushen Injection for the treatment of primary liver cancer has significant clinical curative effect, which can effectively improve patients’ quality of life, reduce the incidence of adverse reactions and alleviate the suffering of patients. It is worthy of clinical application.